Medtronic (NYSE: MDT) is scheduled to report its fiscal 2025 first-quarter results on Tuesday, August 20 (fiscal year ends in April). We expect Medtronic stock to trade higher post-Q1 results announcement, with its revenues and earnings expected to be slightly above the street estimates.
The FDA approval for Medtronic's (MDT) Simplera CGM sets the stage for further regulatory submissions of the updated InPen smart insulin pen app.
Get a deeper insight into the potential performance of Medtronic (MDT) for the quarter ended July 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
In the closing of the recent trading day, Medtronic (MDT) stood at $82.27, denoting a +1.33% change from the preceding trading day.
The latest trading day saw Medtronic (MDT) settling at $80.78, representing a +0.56% change from its previous close.
Merck is finding ways to avoid a fast-approaching patent cliff by continuing to do what it's done for a while. Medtronic is a diversified healthcare giant with several important long-term growth catalysts.
AI healthcare stocks can potentially revolutionize patient care as we know it. The groundbreaking technology is expected to have a pervasive impact on the investment world, with its most profound anticipated transformations in healthcare.
Medtronic's (MDT) stock finally breaking above its 50-day SMA can be a piece of good news for investors, signaling an uptrend.
Medtronic (MDT) closed at $80.32 in the latest trading session, marking a -0.61% move from the prior day.
Medtronic (MDT) concluded the recent trading session at $80, signifying a +1.65% move from its prior day's close.
Across industries, companies will need to adopt AI for growth and survival. A PricewaterhouseCoopers indicates that by 2030, AI could contribute up to $15.7 trillion to the global economy.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.